RE: ACTIV-2 - BMS monoclonals out12 Jan 2022 10:26
Yes, I listened to it with interest Matt.
Stockpiling ready for future variants was discussed. As was, ‘ the use of effective therapeutics are urgently needed to treat patients with COVID-19.’
ACTIV-2, which is focused on outpatients, has been expanded and is currently evaluating two investigational therapeutics: SAB-185, a fully-human polyclonal antibody produced in cattle, and SNG001, an inhalable beta interferon.
Nice to be included in the document.